This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hughes, L. E.
Right arrow Articles by Vowles, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hughes, L. E.
Right arrow Articles by Vowles, J.

 Previous Article  |  Next Article 

Clinical and Diagnostic Laboratory Immunology, November 2001, p. 1181-1188, Vol. 8, No. 6
1071-412X/01/$04.00+0   DOI: 10.1128/CDLI.8.6.1181-1188.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Antibody Responses to Acinetobacter spp. and Pseudomonas aeruginosa in Multiple Sclerosis: Prospects for Diagnosis Using the Myelin-Acinetobacter-Neurofilament Antibody Index

L. E. Hughes,1 S. Bonell,1 R. S. Natt,1 C. Wilson,1 H. Tiwana,1 A. Ebringer,1,* P. Cunningham,1 V. Chamoun,2 E. J. Thompson,2 J. Croker,3 and J. Vowles3

Infection and Immunity Group, Division of Life Sciences, King's College London,1 Department of Neuroimmunology, Institute of Neurology, Queen Square,2 and Department of Geriatric Medicine, University College Hospital,3 London, United Kingdom

Received 20 February 2001/Returned for modification 23 May 2001/Accepted 17 July 2001

Antibody responses to Acinetobacter (five strains), Pseudomonas aeruginosa, Escherichia coli, myelin basic protein (MBP), and neurofilaments were measured in sera from 26 multiple sclerosis (MS) patients, 20 patients with cerebrovascular accidents (CVA), 10 patients with viral encephalitis, and 25 healthy blood donors. In MS patients, elevated levels of antibodies against all strains of Acinetobacter tested were present, as well as antibodies against P. aeruginosa, MBP, and neurofilaments, but not antibodies to E. coli, compared to the CVA group and controls. The myelin-Acinetobacter-neurofilament antibody index appears to distinguish MS patients from patients with CVAs or healthy controls. The relevance of such antibodies to the neuropathology of MS requires further evaluation.

* Corresponding author. Mailing address: Infection and Immunity Group, Division of Health and Life Sciences, King's College London, 150, Stamford St., London SE1 9NN, United Kingdom. Phone: 020-7848-4302. Fax: 020-7848-4500. E-mail: alan.ebringer{at}kcl.ac.uk.

Clinical and Diagnostic Laboratory Immunology, November 2001, p. 1181-1188, Vol. 8, No. 6
1071-412X/01/$04.00+0   DOI: 10.1128/CDLI.8.6.1181-1188.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Ebringer, A., Hughes, L., Rashid, T., Wilson, C. (2005). Acinetobacter Immune Responses in Multiple Sclerosis: Etiopathogenetic Role and Its Possible Use as a Diagnostic Marker. Arch Neurol 62: 33-36 [Abstract] [Full Text]  
  • Reder, A. T., Oger, J. J. (2004). Anti-myelin oligodendrocyte glycoprotein antibodies in multiple sclerosis. Neurology 62: 1922-1923 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»